share_log

Medicenna Therapeutics Analyst Ratings

Medicenna Therapeutics Analyst Ratings

Medicenna Treateutics分析師評級
Benzinga Analyst Ratings ·  2022/11/29 20:56
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/08/2022 481.26% HC Wainwright & Co. $4 → $2.5 Maintains Buy
08/16/2022 830.02% HC Wainwright & Co. $5 → $4 Maintains Buy
06/23/2022 2225.04% Oppenheimer $12 → $10 Maintains Outperform
06/23/2022 1062.52% HC Wainwright & Co. $7 → $5 Maintains Buy
06/01/2021 1527.53% HC Wainwright & Co. $8 → $7 Maintains Buy
12/18/2020 2690.05% Oppenheimer → $12 Initiates Coverage On → Outperform
12/17/2020 2690.05% Oppenheimer → $12 Initiates Coverage On → Outperform
09/10/2020 1760.03% HC Wainwright & Co. → $8 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
11/08/2022 481.26% HC Wainwright公司 $4 → $2.5 維護
08/16/2022 830.02% HC Wainwright公司 $5 → $4 維護
06/23/2022 2225.04% 奧本海默 $12 → $10 維護 跑贏大盤
06/23/2022 1062.52% HC Wainwright公司 $7 → $5 維護
06/01/2021 1527.53% HC Wainwright公司 $8 → $7 維護
12/18/2020 2690.05% 奧本海默 → $12 開始承保 →跑贏大盤
12/17/2020 2690.05% 奧本海默 → $12 開始承保 →跑贏大盤
09/10/2020 1760.03% HC Wainwright公司 → $8 開始承保 →購買

What is the target price for Medicenna Therapeutics (MDNA)?

Medicenna Treeutics(MDNA)的目標價格是多少?

The latest price target for Medicenna Therapeutics (NASDAQ: MDNA) was reported by HC Wainwright & Co. on November 8, 2022. The analyst firm set a price target for $2.50 expecting MDNA to rise to within 12 months (a possible 481.26% upside). 4 analyst firms have reported ratings in the last year.

2022年11月8日,HC Wainwright&Co.報道了Medicenna治療公司(納斯達克:mDNA)的最新目標價。這家分析公司將目標價定為2.5美元,預計mDNA將在12個月內上漲至(可能上漲481.26%)。去年有4家分析公司公佈了評級。

What is the most recent analyst rating for Medicenna Therapeutics (MDNA)?

Medicenna治療公司(MDNA)的最新分析師評級是多少?

The latest analyst rating for Medicenna Therapeutics (NASDAQ: MDNA) was provided by HC Wainwright & Co., and Medicenna Therapeutics maintained their buy rating.

美第奇拿治療公司(納斯達克代碼:mDNA)的最新分析師評級由HC Wainwright&Co.提供,美第奇拿治療公司維持其買入評級。

When is the next analyst rating going to be posted or updated for Medicenna Therapeutics (MDNA)?

Medicenna治療公司(MDNA)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medicenna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medicenna Therapeutics was filed on November 8, 2022 so you should expect the next rating to be made available sometime around November 8, 2023.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閲公共財務報表,與Medicenna Treeutics的高管和客户交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。Medicenna治療公司的上一次評級是在2022年11月8日提交的,所以你應該預計下一次評級將在2023年11月8日左右提供。

Is the Analyst Rating Medicenna Therapeutics (MDNA) correct?

分析師對Medicenna Treeutics(MDNA)的評級正確嗎?

While ratings are subjective and will change, the latest Medicenna Therapeutics (MDNA) rating was a maintained with a price target of $4.00 to $2.50. The current price Medicenna Therapeutics (MDNA) is trading at is $0.43, which is out of the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的Medicenna Treeutics(MDNA)評級保持不變,目標價在4.00美元至2.50美元之間。Medicenna Treateutics(MDNA)目前的交易價格為0.43美元,超出了分析師的預測範圍。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論